Drug Profile
Belinostat - Valerio Therapeutics
Alternative Names: Beleodaq; CLN-9; PDX 101; PX-105684; PXD 101Latest Information Update: 27 Nov 2023
Price :
$50
*
At a glance
- Originator TopoTarget
- Developer Acrotech Biopharma; CIMA- Universidad de Navarra; Emory University; National Cancer Institute (USA); Servier; TopoTarget; Valerio Therapeutics
- Class Acrylamides; Antineoplastics; Hydroxamic acids; Small molecules; Sulfonamides
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Peripheral T-cell lymphoma
- Phase II B-cell lymphoma; Glioblastoma
- Phase I/II Non-small cell lung cancer
- Phase I Breast cancer; Ovarian cancer; Prostate cancer
- Suspended Chondrosarcoma
- No development reported Acute myeloid leukaemia; Bladder cancer; Carcinoma; Colorectal cancer; Cutaneous T-cell lymphoma; Fallopian tube cancer; Liver cancer; Lymphoma; Malignant thymoma; Malignant-mesothelioma; Myelodysplastic syndromes; Peritoneal cancer; Small cell lung cancer; Soft tissue sarcoma; Solid tumours
- Discontinued Multiple myeloma
Most Recent Events
- 13 Oct 2023 Acrotech Biopharma plans a phase III CRESCENDO trial for Peripheral T-cell lymphoma (Combination therapy) in USA in October 2023 (Parenteral) (NCT06072131)
- 04 Oct 2023 Phase-III clinical trials in Peripheral T-cell lymphoma (Combination therapy, First-line therapy) in USA (IV) (NCT06072131)
- 31 Mar 2023 Acrotech Biopharma completes phase-I extension trial inSolid tumours and Haematological malignancies in USA (NCT04184869)